About futibatinib
FGFR1–4 tyrosine kinase inhibitor
Used for
- Treats certain previously treated bile duct cancers with an FGFR2 fusion or rearrangement.
Usual adult dose
20 mg by mouth once daily, continuously, until disease worsens or side effects become unacceptable.
Common side effects
- High phosphate levels
- Nail problems and hair loss
- Dry mouth or eye problems
- Diarrhea, constipation, or fatigue
Important warnings
- Can harm an unborn baby; pregnancy testing and effective contraception are advised.
- May cause serious eye problems; eye examinations are needed before and during treatment.
- High phosphate can cause soft-tissue mineral buildup; blood phosphate monitoring is required.
- Report severe skin, nail, or vision changes promptly.
Pregnancy
May cause fetal harm; avoid during pregnancy. Effective contraception is advised during treatment and for one week after the last dose.
Breastfeeding
Do not breastfeed during treatment and for one week after the last dose.
Interactions
- Avoid strong or moderate CYP3A inhibitors or inducers when possible.
- Avoid drugs that reduce stomach acid, including proton pump inhibitors, H2 blockers, and antacids.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.